Zhou G, Cummings R, Li Y, Mitra S, Wilkinson H A, Elbrecht A, Hermes J D, Schaeffer J M, Smith R G, Moller D E
Department of Biochemistry and Physiology, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
Mol Endocrinol. 1998 Oct;12(10):1594-604. doi: 10.1210/mend.12.10.0176.
Ligand-dependent interactions between nuclear receptors and members of a family of nuclear receptor coactivators are associated with transcriptional activation. Here we used fluorescence resonance energy transfer (FRET) as an approach for detecting and quantitating such interactions. Using the ligand binding domain (LBD) of peroxisome proliferator-activated receptor (PPARgamma) as a model, known agonists (thiazolidinediones and delta12, 14-PGJ2) induced a specific interaction resulting in FRET between the fluorescently labeled LBD and fluorescently labeled coactivators [CREB-binding protein (CBP) or steroid receptor coactivator-1 (SRC-1)]. Specific energy transfer was dose dependent; individual ligands displayed distinct potency and maximal FRET profiles that were identical when results obtained using CBP vs. SRC-1 were compared. In addition, half-maximally effective agonist concentrations (EC59s) correlated well with reported results using cell-based assays. A site-directed AF2 mutant of PPARgamma (E471A) that abrogated ligand-stimulated transcription in transfected cells also failed to induce ligand-mediated FRET between PPARgamma LBD and CBP or SRC-1. Using estrogen receptor (ERalpha) as an alternative system, known agonists induced an interaction between ERalpha LBD and SRC-1, whereas ER antagonists disrupted agonist-induced interaction of ERalpha with SRC-1. In the presence of saturating agonist concentrations, unlabeled CBP or SRC-1 was used to compete with fluorescently labeled coactivators with saturation kinetics. Relative affinities for the individual receptor-coactivator pairs were determined as follows: PPARgamma-CBP = ERalpha-SRC-1 > PPARgamma-SRC-1 >> ERalpha-CBP.
核受体与核受体共激活因子家族成员之间的配体依赖性相互作用与转录激活相关。在此,我们使用荧光共振能量转移(FRET)作为检测和定量此类相互作用的方法。以过氧化物酶体增殖物激活受体(PPARγ)的配体结合域(LBD)为模型,已知激动剂(噻唑烷二酮类和δ12,14-前列腺素J2)诱导了一种特异性相互作用,导致荧光标记的LBD与荧光标记的共激活因子[CREB结合蛋白(CBP)或类固醇受体共激活因子-1(SRC-1)]之间发生FRET。特异性能量转移呈剂量依赖性;各个配体显示出不同的效力和最大FRET谱,当比较使用CBP与SRC-1获得的结果时,这些谱是相同的。此外,半数最大有效激动剂浓度(EC59s)与使用基于细胞的测定法得到的报道结果相关性良好。PPARγ的一个定点AF2突变体(E471A)在转染细胞中消除了配体刺激的转录,也未能诱导PPARγ LBD与CBP或SRC-1之间的配体介导的FRET。以雌激素受体(ERα)作为另一个系统,已知激动剂诱导了ERα LBD与SRC-1之间的相互作用,而ER拮抗剂破坏了激动剂诱导的ERα与SRC-1的相互作用。在存在饱和激动剂浓度的情况下,未标记的CBP或SRC-1用于以饱和动力学与荧光标记的共激活因子竞争。各个受体-共激活因子对的相对亲和力如下确定:PPARγ-CBP = ERα-SRC-1 > PPARγ-SRC-1 >> ERα-CBP。
1)基于FRET的共激活因子关联是表征核受体激动剂或拮抗剂的一种新方法;各个配体显示出的效力可预测体内效应,且最大活性的不同谱提示了受体的不同构象。2)PPARγ与CBP和SRC-1都相互作用;转录激活和共激活因子关联是AF2依赖性的。3)核受体LBD对各个共激活因子具有不同的亲和力;因此,PPARγ对CBP的表观亲和力大于对SRC-1的,而ERα优先与SRC-1相互作用,但与CBP的相互作用非常弱。